Meningococcal polysaccharide vaccine group W-135

Overview

Meningococcal group W-135 polysaccharide is group-specific polysaccharide antigens extracted and purified from Neisseria meningitidis serogroup W-135. N. meningitidis is a bacteria that causes endemic and epidemic diseases including meningitis and meningococcemia. It is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup W-135.

Indication

No indication information available.

Associated Conditions

Invasive Meningococcal Infection caused by Neisseria meningitidis serogroup W-135

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor

No clinical trials found

No clinical trials found for this drug

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
Menactra®, solution for injection	Sanofi Pasteur Inc.	SIN13922P	INJECTION, SOLUTION	4 mcg/dose (0.5 ml)	2/24/2011
Menveo Powder and Solution for Solution for Injection	GSK Vaccines S.r.l. (MenCWY Liquid), GSK Vaccines GmbH (MenA Lyo)	SIN14083P	INJECTION, POWDER, FOR SOLUTION	5 microgram conjugated to 3.3-8.3 microgram	1/20/2012
MENQUADFI SOLUTION FOR INJECTION	Sanofi Pasteur, Inc.	SIN16454P	INJECTION, SOLUTION	10 mcg / 0.5mL	3/29/2022

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
MENVEO Meningococcal (Groups A,C,W-135 and Y) Oligosaccharide CRM197 solution for injection vial	393321	GlaxoSmithKline Australia Pty Ltd	Medicine	A	9/26/2023
NIMENRIX Meningococcal (Groups A, C, W-135, Y) Polysaccharide Tetanus Toxoid Conjugate Vaccine, injection vial and diluent syringe	199742	Pfizer Australia Pty Ltd	Medicine	A	8/29/2013
MenQuadfi meningococcal (Groups A,C,Y,W) polysaccharide tetanus toxoid conjugate vaccine, solution for injection, vial	325682	Sanofi-Aventis Australia Pty Ltd	Medicine	A	10/29/2020
MENVEO meningococcal (Groups A, C, W-135 and Y) oligosaccharide CRM197 conjugate vaccine	192696	GlaxoSmithKline Australia Pty Ltd	Medicine	A	5/23/2012

Health Canada Drug Approvals

Approved Product	Company	DIN	Dosage Form	Strength	Market Date
MENOMUNE-A/C/Y/W-135	aventis pasteur limited	02161184	Powder For Solution - Subcutaneous	2.5 MG / KIT	8/13/1998
NIMENRIX	Pfizer Canada Ulc	02402904	Powder For Solution , Kit - Intramuscular	5 MCG / 0.5 ML	8/22/2013
MENOMUNE-A/C/Y/W-135	Sanofi Pasteur Limited	00588490	Powder For Solution - Subcutaneous	500 MCG / KIT	12/31/1983
MENOMUNE-A/C/Y/W-135	Sanofi Pasteur Limited	01959018	Powder For Solution , Kit - Subcutaneous	50 MCG / 0.5 ML	10/29/1993

CIMA AEMPS Drug Approvals

Approved Product	Company	Registration Number	Pharmaceutical Form	Prescription Type	Status
No CIMA AEMPS (Spain) approvals found for this drug.

Philippines FDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product	Company	Registration Number	Dosage Form	Strength	Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name	MA Holder	MA Number	Pharmaceutical Form	Active Ingredient	Authorization Date
No UK EMC drug information found for this drug.

AI-Powered Research

Premium Access